Cargando…

The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study

OBJECTIVE: At the beginning of the COVID-19 pandemic in the Netherlands, the Dutch Working Party on Antibiotic Policy constructed an advisory document about off-label drug treatment options that was regularly updated with new scientific findings. The aim of this study is to describe the dynamics in...

Descripción completa

Detalles Bibliográficos
Autores principales: Uitvlugt, Elien B, Soeng, Danny Y F, van der Linden, Paul, van de Garde, Ewoudt M W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288218/
https://www.ncbi.nlm.nih.gov/pubmed/34272215
http://dx.doi.org/10.1136/ejhpharm-2021-002781
_version_ 1783724055927455744
author Uitvlugt, Elien B
Soeng, Danny Y F
van der Linden, Paul
van de Garde, Ewoudt M W
author_facet Uitvlugt, Elien B
Soeng, Danny Y F
van der Linden, Paul
van de Garde, Ewoudt M W
author_sort Uitvlugt, Elien B
collection PubMed
description OBJECTIVE: At the beginning of the COVID-19 pandemic in the Netherlands, the Dutch Working Party on Antibiotic Policy constructed an advisory document about off-label drug treatment options that was regularly updated with new scientific findings. The aim of this study is to describe the dynamics in applied COVID-19 pharmacotherapy during the first 100 days of the pandemic and to assess how the national advisory document influenced local hospital policies. METHODS: A multicentre observational cohort study was conducted in six hospitals in the Netherlands. Patients with confirmed COVID-19 admitted between 27 February and 7 June 2020 were studied. Drug prescription data were collected and percentages of patients receiving a specific treatment were calculated. These percentages were plotted together with release dates of the national advisory document. Semi-structured in-depth interviews with hospital pharmacists and infectious diseases specialists were conducted to gain insight into the development and implementation of pharmacotherapy treatment protocols in hospitals. RESULTS: Data from 1511 patients (60% men, mean age 66 years) were analysed. From mid-March (hydroxy)chloroquine was being prescribed in all six hospitals to approximately 70% of patients at admission. Frequencies of other off-label treatments were below 2%. In the week of 6 April 2020, the first hospital discontinued prescribing (hydroxy)chloroquine and the last hospital discontinued in the week of 4 May 2020 (total range −19 to +10 days after the national advisory document advised against its use (1 May 2020)). All interviewees (n=6) stated that the hospitals based their policies mainly on the national advisory document but also assessed scientific literature themselves. Order panels were constructed to support prescribing. CONCLUSION: Dutch hospitals opted en masse for (hydroxy)chloroquine as COVID-19 therapy at the start of the pandemic, although the time until the therapy was no longer prescribed differed by several weeks. The fact that hospitals defined pharmacotherapy regimens based on their own assessment of the scientific literature besides the national advisory document can explain this variation.
format Online
Article
Text
id pubmed-8288218
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82882182021-07-20 The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study Uitvlugt, Elien B Soeng, Danny Y F van der Linden, Paul van de Garde, Ewoudt M W Eur J Hosp Pharm Short Report OBJECTIVE: At the beginning of the COVID-19 pandemic in the Netherlands, the Dutch Working Party on Antibiotic Policy constructed an advisory document about off-label drug treatment options that was regularly updated with new scientific findings. The aim of this study is to describe the dynamics in applied COVID-19 pharmacotherapy during the first 100 days of the pandemic and to assess how the national advisory document influenced local hospital policies. METHODS: A multicentre observational cohort study was conducted in six hospitals in the Netherlands. Patients with confirmed COVID-19 admitted between 27 February and 7 June 2020 were studied. Drug prescription data were collected and percentages of patients receiving a specific treatment were calculated. These percentages were plotted together with release dates of the national advisory document. Semi-structured in-depth interviews with hospital pharmacists and infectious diseases specialists were conducted to gain insight into the development and implementation of pharmacotherapy treatment protocols in hospitals. RESULTS: Data from 1511 patients (60% men, mean age 66 years) were analysed. From mid-March (hydroxy)chloroquine was being prescribed in all six hospitals to approximately 70% of patients at admission. Frequencies of other off-label treatments were below 2%. In the week of 6 April 2020, the first hospital discontinued prescribing (hydroxy)chloroquine and the last hospital discontinued in the week of 4 May 2020 (total range −19 to +10 days after the national advisory document advised against its use (1 May 2020)). All interviewees (n=6) stated that the hospitals based their policies mainly on the national advisory document but also assessed scientific literature themselves. Order panels were constructed to support prescribing. CONCLUSION: Dutch hospitals opted en masse for (hydroxy)chloroquine as COVID-19 therapy at the start of the pandemic, although the time until the therapy was no longer prescribed differed by several weeks. The fact that hospitals defined pharmacotherapy regimens based on their own assessment of the scientific literature besides the national advisory document can explain this variation. BMJ Publishing Group 2022-03 2021-07-16 /pmc/articles/PMC8288218/ /pubmed/34272215 http://dx.doi.org/10.1136/ejhpharm-2021-002781 Text en © European Association of Hospital Pharmacists 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Short Report
Uitvlugt, Elien B
Soeng, Danny Y F
van der Linden, Paul
van de Garde, Ewoudt M W
The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
title The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
title_full The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
title_fullStr The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
title_full_unstemmed The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
title_short The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
title_sort dynamics in applied covid-19 pharmacotherapy and the influence of national guidance in the netherlands: a quantitative and qualitative study
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288218/
https://www.ncbi.nlm.nih.gov/pubmed/34272215
http://dx.doi.org/10.1136/ejhpharm-2021-002781
work_keys_str_mv AT uitvlugtelienb thedynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy
AT soengdannyyf thedynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy
AT vanderlindenpaul thedynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy
AT vandegardeewoudtmw thedynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy
AT uitvlugtelienb dynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy
AT soengdannyyf dynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy
AT vanderlindenpaul dynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy
AT vandegardeewoudtmw dynamicsinappliedcovid19pharmacotherapyandtheinfluenceofnationalguidanceinthenetherlandsaquantitativeandqualitativestudy